Market Research Logo

Choroidal Neovascularization - Pipeline Review, H2 2015

Choroidal Neovascularization - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Choroidal Neovascularization - Pipeline Review, H2 2015’, provides an overview of the Choroidal Neovascularization’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Choroidal Neovascularization, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Choroidal Neovascularization and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Choroidal Neovascularization
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Choroidal Neovascularization and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Choroidal Neovascularization products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Choroidal Neovascularization pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Choroidal Neovascularization
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Choroidal Neovascularization pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Choroidal Neovascularization Overview
Therapeutics Development
Pipeline Products for Choroidal Neovascularization - Overview
Pipeline Products for Choroidal Neovascularization - Comparative Analysis
Choroidal Neovascularization - Therapeutics under Development by Companies
Choroidal Neovascularization - Therapeutics under Investigation by Universities/Institutes
Choroidal Neovascularization - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Choroidal Neovascularization - Products under Development by Companies
Choroidal Neovascularization - Products under Investigation by Universities/Institutes
Choroidal Neovascularization - Companies Involved in Therapeutics Development
Affitech A/S
Aprogen, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
Iconic Therapeutics, Inc.
Mabion SA
Navigen Pharmaceuticals, Inc.
Noxxon Pharma AG
Promedior, Inc.
Regeneron Pharmaceuticals, Inc.
Sanwa Kagaku Kenkyusho Co., Ltd.
Choroidal Neovascularization - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
aflibercept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oligonucleotides for Ophthalmology and Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Doxarubicin Pegylated - Drug Profile
Product Description
Mechanism of Action
R&D Progress
hI-con1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MAb-30D8 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NAV-2729 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Netrin-4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NM-9405 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NOXD-20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptides to Target VEGF for Choroidal Neovascularization - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PGN-635 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRM-167 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranibizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Choroidal Neovascularization - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG-7716 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SK-1011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Inflammation and Choroidal Neovascularization - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Choroidal Neovascularization - Recent Pipeline Updates
Choroidal Neovascularization - Dormant Projects
Choroidal Neovascularization - Discontinued Products
Choroidal Neovascularization - Product Development Milestones
Featured News & Press Releases
Sep 25, 2015: Bayer’s Eye Drug Recommended for EU Approval in Fifth Indication
Mar 11, 2015: Bayer Submits Aflibercept Solution for Intravitreal Injection for the Treatment of Myopic Choroidal Neovascularization in the EU
Nov 18, 2014: Intravitreal VEGF Inhibitor EYLEA Obtains Additional Indication of Diabetic Macular Edema, Its Fourth Indication
Sep 22, 2014: Regeneron Announces EYLEA (aflibercept) Injection Approved for the Treatment of Patients with Myopic Choroidal Neovascularization in Japan
Nov 26, 2013: NICE gives green light to ranibizumab for eye condition in final guidance
Nov 18, 2013: Data at 48 weeks for Phase 3 MYRROR trial in mCNV demonstrate long-term efficacy of VEGF Trap-Eye
Jul 05, 2013: Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization
Jun 06, 2013: Regeneron And Bayer Report Positive Phase III Results For Eylea Injection In Myopic Choroidal Neovascularization
May 31, 2013: Novartis Receives Positive CHMP Opinion For Lucentis To Treat Myopic Choroidal Neovascularization Showing Vision Gains With Only Two Injections
Jan 03, 2012: Regeneron Announces Settlement Of Patent Litigation With Genentech For US Ophthalmic Sales Of EYLEA Injection
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Choroidal Neovascularization, H2 2015
Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Choroidal Neovascularization - Pipeline by Affitech A/S, H2 2015
Choroidal Neovascularization - Pipeline by Aprogen, Inc., H2 2015
Choroidal Neovascularization - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Choroidal Neovascularization - Pipeline by Genentech, Inc., H2 2015
Choroidal Neovascularization - Pipeline by Iconic Therapeutics, Inc., H2 2015
Choroidal Neovascularization - Pipeline by Mabion SA, H2 2015
Choroidal Neovascularization - Pipeline by Navigen Pharmaceuticals, Inc., H2 2015
Choroidal Neovascularization - Pipeline by Noxxon Pharma AG, H2 2015
Choroidal Neovascularization - Pipeline by Promedior, Inc., H2 2015
Choroidal Neovascularization - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Choroidal Neovascularization - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Choroidal Neovascularization Therapeutics - Recent Pipeline Updates, H2 2015
Choroidal Neovascularization - Dormant Projects, H2 2015
Choroidal Neovascularization - Dormant Projects (Contd..1), H2 2015
Choroidal Neovascularization - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Choroidal Neovascularization, H2 2015
Number of Products under Development for Choroidal Neovascularization - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report